Maywufa Company Ltd. (1731.TW)
TWD 21.9
(1.62%)
TWD 21.9
(1.62%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 264.18 Million TWD | 433.73% |
| 2022 | 49.49 Million TWD | -37.46% |
| 2021 | 79.15 Million TWD | 460.25% |
| 2020 | -21.97 Million TWD | -111.92% |
| 2019 | 184.28 Million TWD | 32.24% |
| 2018 | 139.36 Million TWD | 230.67% |
| 2017 | 42.14 Million TWD | -51.28% |
| 2016 | 86.51 Million TWD | 168.12% |
| 2015 | 32.26 Million TWD | 128.54% |
| 2014 | -113.05 Million TWD | -197.27% |
| 2013 | 116.22 Million TWD | 139.7% |
| 2012 | -292.73 Million TWD | -93.65% |
| 2011 | -151.17 Million TWD | -191.87% |
| 2010 | 164.54 Million TWD | -41.64% |
| 2009 | 281.97 Million TWD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 386.96 Million TWD | 8.4% |
| 2024 Q1 | 356.96 Million TWD | 35.12% |
| 2023 FY | 264.18 Million TWD | 433.73% |
| 2023 Q1 | 74.79 Million TWD | 51.1% |
| 2023 Q2 | 115.89 Million TWD | 54.96% |
| 2023 Q4 | 264.18 Million TWD | -1.28% |
| 2023 Q3 | 267.61 Million TWD | 130.91% |
| 2022 Q3 | -24.21 Million TWD | 86.81% |
| 2022 Q2 | -183.5 Million TWD | -255.92% |
| 2022 FY | 49.49 Million TWD | -37.46% |
| 2022 Q4 | 49.49 Million TWD | 304.44% |
| 2022 Q1 | 117.69 Million TWD | 48.7% |
| 2021 Q1 | 152.84 Million TWD | 795.67% |
| 2021 FY | 79.15 Million TWD | 460.25% |
| 2021 Q2 | 86.39 Million TWD | -43.47% |
| 2021 Q4 | 79.15 Million TWD | -31.84% |
| 2021 Q3 | 116.13 Million TWD | 34.41% |
| 2020 FY | -21.97 Million TWD | -111.92% |
| 2020 Q1 | 179.99 Million TWD | -2.33% |
| 2020 Q2 | 96.82 Million TWD | -46.21% |
| 2020 Q3 | -32.74 Million TWD | -133.82% |
| 2020 Q4 | -21.97 Million TWD | 32.9% |
| 2019 Q1 | 240.94 Million TWD | 72.89% |
| 2019 FY | 184.28 Million TWD | 32.24% |
| 2019 Q2 | 176.04 Million TWD | -26.94% |
| 2019 Q4 | 184.28 Million TWD | 21.71% |
| 2019 Q3 | 151.41 Million TWD | -13.99% |
| 2018 Q4 | 139.36 Million TWD | -18.0% |
| 2018 Q1 | 148 Million TWD | 251.19% |
| 2018 Q2 | 123.76 Million TWD | -16.38% |
| 2018 Q3 | 169.96 Million TWD | 37.32% |
| 2018 FY | 139.36 Million TWD | 230.67% |
| 2017 Q1 | 54.21 Million TWD | -37.33% |
| 2017 FY | 42.14 Million TWD | -51.28% |
| 2017 Q4 | 42.14 Million TWD | -68.56% |
| 2017 Q3 | 134.06 Million TWD | 75.39% |
| 2017 Q2 | 76.43 Million TWD | 40.99% |
| 2016 Q2 | 85.93 Million TWD | 66.08% |
| 2016 Q1 | 51.74 Million TWD | 60.38% |
| 2016 FY | 86.51 Million TWD | 168.12% |
| 2016 Q4 | 86.51 Million TWD | -20.19% |
| 2016 Q3 | 108.39 Million TWD | 26.13% |
| 2015 Q4 | 32.26 Million TWD | 199.36% |
| 2015 FY | 32.26 Million TWD | 128.54% |
| 2015 Q2 | 1.33 Million TWD | 101.8% |
| 2015 Q3 | -32.47 Million TWD | -2530.76% |
| 2015 Q1 | -74.22 Million TWD | 34.35% |
| 2014 Q3 | 44.84 Million TWD | -46.84% |
| 2014 Q2 | 84.36 Million TWD | -20.87% |
| 2014 FY | -113.05 Million TWD | -197.27% |
| 2014 Q1 | 106.61 Million TWD | -8.27% |
| 2014 Q4 | -113.05 Million TWD | -352.11% |
| 2013 Q3 | 168.62 Million TWD | 22.15% |
| 2013 Q4 | 116.22 Million TWD | -31.07% |
| 2013 FY | 116.22 Million TWD | 139.7% |
| 2013 Q1 | 171.37 Million TWD | 158.54% |
| 2013 Q2 | 138.04 Million TWD | -19.45% |
| 2012 Q1 | -155.83 Million TWD | -3.08% |
| 2012 Q3 | -106.42 Million TWD | 10.06% |
| 2012 Q4 | -292.73 Million TWD | -175.05% |
| 2012 FY | -292.73 Million TWD | -93.65% |
| 2012 Q2 | -118.32 Million TWD | 24.07% |
| 2011 Q4 | -151.17 Million TWD | -23.3% |
| 2011 FY | -151.17 Million TWD | -191.87% |
| 2011 Q1 | -2.11 Million TWD | -101.29% |
| 2011 Q3 | -122.6 Million TWD | -12.01% |
| 2011 Q2 | -109.45 Million TWD | -5070.24% |
| 2010 Q4 | 164.54 Million TWD | 0.0% |
| 2010 FY | 164.54 Million TWD | -41.64% |
| 2009 FY | 281.97 Million TWD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Grape King Bio Ltd | -4.62 Billion TWD | 105.711% |
| Standard Chem & Pharm CO., LTD. | -954.74 Million TWD | 127.671% |
| ScinoPharm Taiwan, Ltd. | -3.32 Billion TWD | 107.956% |
| Lotus Pharmaceutical Co., Ltd. | 9.81 Billion TWD | 97.308% |
| LIWANLI Innovation Co., Ltd. | -244.02 Million TWD | 208.262% |
| YungShin Global Holding Corporation | -247.5 Million TWD | 206.741% |
| PhytoHealth Corporation | -34.64 Million TWD | 862.637% |
| SCI Pharmtech, Inc. | 100.41 Million TWD | -163.088% |
| Formosa Laboratories, Inc. | 2.53 Billion TWD | 89.592% |
| PharmaEssentia Corporation | -18.46 Billion TWD | 101.431% |
| Bora Pharmaceuticals Co., LTD. | 1.95 Billion TWD | 86.497% |